Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (1)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018 Capital Markets and Public M&A

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Related

Vinge has advised Terranor Group AB in connection with its listing on Nasdaq First North Growth Market

 Vinge has advised Terranor Group AB (publ) (“Terranor”) connection with its listing on Nasdaq First North Growth Market. The first day of trading in Terranor's shares is today 30 June 2025.
June 30, 2025

Vinge advises Keyto Group in connection with the acquisition of GreenThumb

KEYTO Group expands into the UK market as GreenThumb joins the group. This partnership marks KEYTO’s first entry in the UK and reinforces its ambition to build the leading, tech-enabled one-stop destination for home-related services internationally.
June 30, 2025

Vinge advises Odevo in the acquisition of Portik Group

 Vinge has advised Odevo, the internationally leading company within residential property management, in connection with the acquisition of Portik Group. Through the acquisition, Odevo continues its international expansion by establishing itself in Spain, Italy, Portugal and Mexico.
June 27, 2025